The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Alprostadil

Criteria

Inclusion Criteria:

• Older than 20 years old

• Compressive cervical myelopathy, confirmed by MRI, including C1-C2 instability, ossification of posterior longitudinal ligament

• Plan to undergo cervical surgery for myelopathy

• JOA score less than 15 points

• Signed informed consent of patient or legal guardian

Exclusion Criteria:

• Infection or malignancy

• Taking Limaprost before surgery

• Pregnancy or expected to be pregnant or breast feeding

• severe cardiovascular, pulmonary, renal disease or distress, brain pathology

• any related coagulopathy

• any drug to cause bleeding tendency

• severe pain from other disease

• any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study

• patient cannot follow study protocol, for any reason